
    
      This study aims to demonstrate the efficacy and safety of BIA 9-1067 used in addition to
      L-DOPA/DDCI to control the "wearing-off" phenomenon in patients with PD.

      DDCI (DOPA decarboxylase inhibitors): benserazide and carbidopa
    
  